DETERMINANTS OF 12-MONTHS PERSISTENCE IN PSORIATIC ARTHRITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS

被引:0
|
作者
Fautrel, B. [1 ,2 ]
Belhassen, M. [3 ,4 ]
Hudry, C. [5 ]
Woronoff, M-C. [6 ]
Gouyette, N. [7 ]
Clement, A. [7 ]
Van Ganse, E. [8 ]
Tubach, F. [9 ,10 ,11 ]
机构
[1] UPMC Univ Paris 06, Sorbonne Univ, Paris, France
[2] Pitie Salpetriere Univ Hosp, AP HP, Rheumatol Dept, Paris, France
[3] Univ Claude Bernard Lyon 1, Hlth Serv & Performance Res, Hesper 7425, Lyon, France
[4] PELyon, Pharmacoepidemiol Lyon, Lyon, France
[5] Hop Cochin, AP HP, Paris, France
[6] Univ Franche Comte, CHU Besancon, Comue Ubfc, INSERM,UMR 1098, Besancon, France
[7] Merck Sharp & Dohme Ltd, Paris, France
[8] Univ Claude Bernard Lyon 1, Pharmacoepidemiol Lyon, Hlth Serv & Performance Res, Hesper 7425,PELyon, Lyon, France
[9] Hop La Pitie Salpetriere, APHP, Dept Biostat Sante Publ & Informat Med, Ctr Pharmacoepidemiol Cephepi, Paris, France
[10] INSERM, UMR 1123, ECEVE, Paris, France
[11] Sorbonne Univ, Univ Pierre & Marie Curie Paris 6, Paris, France
关键词
D O I
10.1136/annrheumdis-2017-eular.5081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
SAT0685
引用
收藏
页码:1034 / 1034
页数:1
相关论文
共 50 条
  • [1] DETERMINANTS OF 12-MONTHS PERSISTENCE IN RHEUMATOID ARTHRITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Fautrel, B.
    Belhassen, M.
    Hudry, C.
    Woronoff, M-C.
    Gouyette, N.
    Clement, A.
    Van Ganse, E.
    Tubach, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1033 - 1034
  • [2] Determinants of 12-Months Persistence in Psoriatic Arthritis Patients Initiating Subcutaneous TNF-α Inhibitors
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Gouyette, Najat
    Clement, Aurore
    Van Ganse, Eric
    Tubach, Florence
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 515 - 516
  • [3] DETERMINANTS OF 12-MONTHS PERSISTENCE IN ANKYLOSING SPONDYLITIS PATIENTS INITIATING SUBCUTANEOUS TNF-ALPHA INHIBITORS
    Fautrel, B.
    Belhassen, M.
    Hudry, C.
    Woronoff, M. -C.
    Gouyette, N.
    Clement, A.
    Van Ganse, E.
    Tubach, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 754 - 755
  • [4] Determinants of 12-Months Persistence in Rheumatoid Arthritis Patients Initiating Subcutaneous TNF-α Inhibitors
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Gouyette, Najat
    Clement, Aurore
    Van Ganse, Eric
    Tubach, Florence
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 514 - 514
  • [5] Determinants of 12-Months Persistence in Ankylosing Spondylitis Patients Initiating Subcutaneous TNF-α Inhibitors
    Fautrel, Bruno
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Gouyette, Najat
    Clement, Aurore
    Van Ganse, Eric
    Tubach, Florence
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 514 - 515
  • [6] TREATMENT PERSISTENCE OF SUBCUTANEOUS TNF-ALPHA INHIBITORS AND JAK INHIBITORS AMONG AUSTRALIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Puig, Andrea
    Chien, Tirian
    O'Sullivan, Catherine
    [J]. INTERNAL MEDICINE JOURNAL, 2020, 50 : 24 - 24
  • [7] Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Lamezec, Liliane
    Gouyette, Najat
    Ginoux, Marine
    Van Ganse, Eric
    Tubach, Florence
    Fautrel, Bruno
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [8] TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis
    Lubrano, Ennio
    Scriffignano, Silvia
    Perrotta, Fabio Massimo
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (12) : 1303 - 1312
  • [9] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Svedbom, Axel
    Dalen, Johan
    Ivergard, Moa
    Borse, Rebekah H.
    Black, Christopher M.
    Luttropp, Karin
    Kachroo, Sumesh
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 45 - 54
  • [10] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Axel Svedbom
    Johan Dalén
    Moa Ivergård
    Rebekah H. Borse
    Christopher M. Black
    Karin Luttropp
    Sumesh Kachroo
    [J]. The European Journal of Health Economics, 2020, 21 : 45 - 54